Clinigen’s ALS therapy bags US orphan status
Clinigen has bagged a US orphan drug designation (ODD) for its investigational Amyotrophic Lateral Sclerosis (ALS) treatment aldesleukin.
Read More
Tag: orphan drug status
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
